Concepedia

Synthesis, SAR, and X-ray structure of novel potent DPPIV inhibitors: Oxadiazolyl ketones

Ki Dong Koo, Min Jung Kim, Sung-Sub Kim, Kyoung-Hee Kim, Sang Yong Hong, Gwong‐Cheung Hur, Hyeon Joo Yim, Geun Tae Kim, Hee Oon Han, Oh-Seok Kwon,

Bioorganic & Medicinal Chemistry Letters · 2007 · 17 citations · 13 references

DOIFull text

Open access

Concepts

References

13

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Mette Zander, Sten Madsbad, Jan Lysgaard Madsen et al. · The Lancet · 2002 · 1.3K citations

, , +16

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Rolf Mentlein, Baptist Gallwitz, Wolfgang E. Schmidt · European Journal of Biochemistry · 1993 · 1.2K citations · Full text

, , +17

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Timothy J. Kieffer, Christopher H.S. McIntosh, Raymond A. Pederson · Endocrinology · 1995 · 1.1K citations

, , +17

(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text

, , +15

1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(<i>S</i>)-pyrrolidine:  A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties

Edwin B. Villhauer, J. A. Brinkman, Goli B. Naderi et al. · Journal of Medicinal Chemistry · 2003 · 613 citations · Full text

, , +12